ABSTRACT
This report describes two patients with multidrug resistant tuberculosis who were successfully treated with the addition of amoxicillin-clavulanic acid to second-line drugs. Mycobacterium tuberculosis possesses a beta-lactamase contributing to its resistance to beta-lactam antibiotics. The combination of clavulanic acid, a beta-lactamase inhibitor, and amoxicillin has been shown bactericidal for M tuberculosis in vitro. These data suggest that resistant tuberculosis may warrant a trial of treatment including amoxicillin-clavulanic acid.
Subject(s)
Amoxicillin/therapeutic use , Clavulanic Acids/therapeutic use , Mycobacterium tuberculosis/drug effects , Tuberculosis, Pulmonary/drug therapy , beta-Lactamase Inhibitors , Adult , Amoxicillin/administration & dosage , Antitubercular Agents/therapeutic use , Clavulanic Acid , Clavulanic Acids/administration & dosage , Drug Combinations , Drug Resistance, Microbial , Drug Therapy, Combination , Female , Humans , MaleABSTRACT
An 18-year-old man had an eventually fatal case of Peptococcus magnus endocarditis. Multiple emboli and continued valve destruction occurred during appropriate therapy. Penicillin therapy was associated with fever and neutropenia, thought to be due to an immunologic mechanism.
Subject(s)
Endocarditis, Bacterial/etiology , Peptococcus , Adolescent , Endocarditis, Bacterial/diagnosis , Humans , MaleABSTRACT
Twelve healthy volunteers received single 400-mg oral doses of norfloxacin. During the ensuing 48 h, from 8.3 to 53.3% (mean, 28%) of this dose was recovered in the feces. Peak drug concentrations in fecal specimens ranged from 207 to 2,716 micrograms/g.
